Check Out What Whales Are Doing With JNJ

High-rolling investors have positioned themselves bearish on Johnson & Johnson JNJ, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in JNJ often signals that someone has privileged information.

Today, Benzinga's options scanner spotted 9 options trades for Johnson & Johnson. This is not a typical pattern.

The sentiment among these major traders is split, with 44% bullish and 55% bearish. Among all the options we identified, there was one put, amounting to $45,878, and 8 calls, totaling $412,802.

Expected Price Movements

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $155.0 to $165.0 for Johnson & Johnson over the recent three months.

Insights into Volume & Open Interest

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Johnson & Johnson's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Johnson & Johnson's substantial trades, within a strike price spectrum from $155.0 to $165.0 over the preceding 30 days.

Johnson & Johnson Option Activity Analysis: Last 30 Days

Noteworthy Options Activity:

About Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.

Having examined the options trading patterns of Johnson & Johnson, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance

Where Is Johnson & Johnson Standing Right Now?

• With a trading volume of 1,364,100, the price of JNJ is up by 0.27%, reaching $161.4.
• Current RSI values indicate that the stock is may be approaching overbought.
• Next earnings report is scheduled for 19 days from now.

Expert Opinions on Johnson & Johnson

A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $173.0.

• Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Johnson & Johnson with a target price of $181.
• An analyst from Wells Fargo has revised its rating downward to Equal-Weight, adjusting the price target to $163.
• An analyst from Raymond James has decided to maintain their Outperform rating on Johnson & Johnson, which currently sits at a price target of $175.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Johnson & Johnson options trades with real-time alerts from Benzinga Pro.